HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir
暂无分享,去创建一个
A. De Luca | M. Zazzi | K. Theys | R. Camacho | Z. Grossman | J. Snoeck | A. Vandamme | A. Sönnerborg | E. Schülter | D. Struck | M. Zazzi | A. De Luca | A. Abecasis | B. Clotet | C. Torti | J. Vercauteren | K. Theys | J. Vercauteren | J. Snoeck | R. J. Camacho | C. Torti | E. Schülter | B. Clotet | A. Sönnerborg | Z. Grossman | D. Struck | A.-M. Vandamme | A. B. Abecasis
[1] P. Easterbrook,et al. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy , 2010, Journal of the International AIDS Society.
[2] A. Cheng,et al. K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials. , 2007, AIDS.
[3] B. Gazzard,et al. The risks and incidence of K65R and L74V mutations and subsequent virologic responses. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] D. Kuritzkes,et al. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen , 2012, AIDS.
[5] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[6] B. Brenner,et al. The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications. , 2009, HIV therapy.
[7] A. Antinori,et al. Early Virological Failure after Tenofovir + Didanosine + Efavirenz Combination in HIV-Positive Patients upon Starting Antiretroviral Therapy , 2005, Antiviral therapy.
[8] P. Libin,et al. The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir. , 2009, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[9] H. Günthard,et al. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] K. Theys,et al. Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. , 2013, The Journal of antimicrobial chemotherapy.
[11] Anne-Mieke Vandamme,et al. Antiretroviral resistance in different HIV-1 subtypes: impact on therapy outcomes and resistance testing interpretation , 2007, Current opinion in HIV and AIDS.
[12] Ravindra K. Gupta,et al. K65R and Y181C are less prevalent in HAART-experienced HIV-1 subtype A patients , 2005, AIDS.